{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:12:33Z","timestamp":1791087153012,"version":"4.1.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012618","name":"National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012618","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The recent introduction of biological agents has revolutionized the treatment of chronic immune-inflammatory diseases; however, this new therapy did not come without significant side effects.<\/jats:p><jats:p>Through large controlled studies indicating decrease in the number of uveitis flares, the role of TNF inhibitors therapy for non-infectious uveitis gained more ground. Paradoxically to its therapeutic effect, there are reports associating these drugs with the onset or recurrence of inflammatory eye disease.<\/jats:p><jats:p>A number of studies have suggested possible roles for anti-TNF-\u03b1 agents in precipitating or worsening an underlying inflammatory process, including the hypothesis of a disequilibrium in cytokine balance, but to date the mechanisms responsible for these adverse events are not fully understood.<\/jats:p><jats:p>A PubMed literature search was performed using the following terms: ophthalmic complication, uveitis, inflammatory eye disease, optic neuritis, neuropathy, adverse events, anti-TNF, TNF alpha inhibitor, infliximab, etanercept, adalimumab, golimumab, certolizumab, and biologics. The data presented in this study was mainly derived from the use of TNF inhibitors in rheumatology, essentially because these drugs have been used for a longer period in this medical field.<\/jats:p><jats:p>Many of the ocular adverse events reported on this review may be considered a paradoxical effect of anti-TNF therapy. We found a variety of data associating new onset of uveitis with anti-TNF therapy for rheumatic conditions, predominantly under etanercept.<\/jats:p><jats:p>In conclusion, although there is increasing data on ocular adverse events, it remains to be seen whether the suggested link between TNF inhibitors and the onset of ocular inflammation is substantiated by more quality data. Nevertheless, the awareness of potential treatment side effects with anti-TNF should be highlighted.<\/jats:p>","DOI":"10.1186\/s12348-020-00202-6","type":"journal-article","created":{"date-parts":[[2020,4,26]],"date-time":"2020-04-26T23:02:39Z","timestamp":1587942159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["A review of ocular adverse events of biological anti-TNF drugs"],"prefix":"10.1186","volume":"10","author":[{"given":"Fernanda","family":"Nicolela Susanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Pavesio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"202_CR1","doi-asserted-by":"publisher","unstructured":"Bragazzi NL, Watad A, Brigo F, Adawi M, Amital H, Shoenfeld Y (2017) Public health awareness of autoimmune diseases after the death of a celebrity. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-016-3513-5","DOI":"10.1007\/s10067-016-3513-5"},{"key":"202_CR2","doi-asserted-by":"publisher","unstructured":"LaMattina KC, Goldstein DA (2017) Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. https:\/\/doi.org\/10.1080\/1744666X.2017.1288097","DOI":"10.1080\/1744666X.2017.1288097"},{"key":"202_CR3","doi-asserted-by":"publisher","unstructured":"Shim H (2011) One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med. https:\/\/doi.org\/10.3858\/emm.2011.43.10.063","DOI":"10.3858\/emm.2011.43.10.063"},{"key":"202_CR4","doi-asserted-by":"publisher","unstructured":"Connor V (2011) Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int. https:\/\/doi.org\/10.1007\/s00296-009-1292-x","DOI":"10.1007\/s00296-009-1292-x"},{"key":"202_CR5","doi-asserted-by":"publisher","unstructured":"Toussirot \u00c9, Aubin F (2016) Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2015-000239","DOI":"10.1136\/rmdopen-2015-000239"},{"key":"202_CR6","doi-asserted-by":"publisher","unstructured":"Garc\u00eda-Doval I, Hern\u00e1ndez MV, Vanaclocha F et al (2017) Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.14776","DOI":"10.1111\/bjd.14776"},{"key":"202_CR7","doi-asserted-by":"publisher","unstructured":"Van Deventer SJH (1997) Tumour necrosis factor and Crohn\u2019s disease. Gut. https:\/\/doi.org\/10.1136\/gut.40.4.443","DOI":"10.1136\/gut.40.4.443"},{"key":"202_CR8","doi-asserted-by":"publisher","unstructured":"Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-\u03b1 therapy. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keg263","DOI":"10.1093\/rheumatology\/keg263"},{"key":"202_CR9","doi-asserted-by":"publisher","unstructured":"Kalliolias GD, Ivashkiv LB (2016) TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. https:\/\/doi.org\/10.1038\/nrrheum.2015.169","DOI":"10.1038\/nrrheum.2015.169"},{"key":"202_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/rheumatology\/31.5.293","volume":"31","author":"FM Brennan","year":"1992","unstructured":"Brennan FM, Maini RN, Feldmann M (1992) TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol 31:293","journal-title":"Br J Rheumatol"},{"key":"202_CR11","doi-asserted-by":"publisher","unstructured":"Meier FM, Frerix M, Hermann W, M\u00fcller-Ladner U (2013) Current immunotherapy in rheumatoid arthritis. Immunotherapy. https:\/\/doi.org\/10.2217\/imt.13.94","DOI":"10.2217\/imt.13.94"},{"key":"202_CR12","doi-asserted-by":"publisher","unstructured":"Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C (2013) Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202545","DOI":"10.1136\/annrheumdis-2012-202545"},{"key":"202_CR13","doi-asserted-by":"publisher","unstructured":"Malviya G, Salemi S, Lagan\u00e0 B, Diamanti AP, D\u2019Amelio R, Signore A (2013) Biological therapies for rheumatoid arthritis: progress to date. BioDrugs. https:\/\/doi.org\/10.1007\/s40259-013-0021-x","DOI":"10.1007\/s40259-013-0021-x"},{"key":"202_CR14","doi-asserted-by":"publisher","unstructured":"Lim H, Lee SH, Lee HT et al (2018) Structural biology of the TNF\u03b1 antagonists used in the treatment of rheumatoid arthritis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms19030768","DOI":"10.3390\/ijms19030768"},{"key":"202_CR15","doi-asserted-by":"publisher","unstructured":"Miserocchi E, Fogliato G, Modorati G, Bandello F (2013) Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. https:\/\/doi.org\/10.5301\/ejo.5000278","DOI":"10.5301\/ejo.5000278"},{"key":"202_CR16","doi-asserted-by":"publisher","unstructured":"Foster CS, Kothari S, Anesi SD et al (2016) The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv Ophthalmol. https:\/\/doi.org\/10.1016\/j.survophthal.2015.07.001","DOI":"10.1016\/j.survophthal.2015.07.001"},{"key":"202_CR17","doi-asserted-by":"publisher","unstructured":"Braun J, Baraliakos X, Listing J, Sieper J (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.21197","DOI":"10.1002\/art.21197"},{"key":"202_CR18","doi-asserted-by":"publisher","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1509852","DOI":"10.1056\/NEJMoa1509852"},{"key":"202_CR19","doi-asserted-by":"publisher","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(16)31339-3","DOI":"10.1016\/S0140-6736(16)31339-3"},{"key":"202_CR20","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.2147\/DDDT.S160431","volume":"12","author":"S Ming","year":"2018","unstructured":"Ming S, Xie K, He H, Li Y, Lei B (2018) Efficacy and safety of adalimumab in the treatment of non-infectious uveitis: a meta-analysis and systematic review. Drug Des Devel Ther 12:2005\u20132016. https:\/\/doi.org\/10.2147\/DDDT.S160431","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"202_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40674-017-0057-z","volume":"3","author":"AB Sood","year":"2017","unstructured":"Sood AB, Angeles-Han ST (2017) An update on treatment of pediatric chronic non-infectious uveitis. Curr Treat options Rheumatol 3(1):1\u201316. https:\/\/doi.org\/10.1007\/s40674-017-0057-z","journal-title":"Curr Treat options Rheumatol"},{"key":"202_CR22","doi-asserted-by":"publisher","unstructured":"Schwartzman S, Schwartzman M (2015) The use of biologic therapies in uveitis. Clin Rev Allergy Immunol. https:\/\/doi.org\/10.1007\/s12016-014-8455-6","DOI":"10.1007\/s12016-014-8455-6"},{"key":"202_CR23","doi-asserted-by":"publisher","unstructured":"McNally TW, Damato EM, Murray PI, Denniston AK, Barry RJ (2017) An update on the use of biologic therapies in the management of uveitis in Beh\u00e7et\u2019s disease: a comprehensive review. Orphanet J Rare Dis. https:\/\/doi.org\/10.1186\/s13023-017-0681-6","DOI":"10.1186\/s13023-017-0681-6"},{"key":"202_CR24","doi-asserted-by":"publisher","unstructured":"Sakai T, Watanabe H, Kuroyanagi K et al (2013) Health- and vision-related quality of life in patients receiving infliximab therapy for Beh\u00e7et uveitis. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302515","DOI":"10.1136\/bjophthalmol-2012-302515"},{"key":"202_CR25","doi-asserted-by":"publisher","unstructured":"Tappeiner C, Schenck S, Niewerth M, Heiligenhaus A, Minden K, Klotsche J (2016) Impact of antiinflammatory treatment on the onset of uveitis in juvenile idiopathic arthritis: longitudinal analysis from a nationwide pediatric rheumatology database. Arthritis Care Res. https:\/\/doi.org\/10.1002\/acr.22649","DOI":"10.1002\/acr.22649"},{"key":"202_CR26","doi-asserted-by":"publisher","unstructured":"Cordero-Coma M, Salom D, D\u00edaz-Llopis M, L\u00f3pez-Prats MJ, Calleja S (2011) Golimumab for uveitis. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2011.05.019","DOI":"10.1016\/j.ophtha.2011.05.019"},{"key":"202_CR27","doi-asserted-by":"publisher","unstructured":"Tlucek PS, Stone DU (2012) Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea. https:\/\/doi.org\/10.1097\/ICO.0b013e318211400a","DOI":"10.1097\/ICO.0b013e318211400a"},{"key":"202_CR28","doi-asserted-by":"publisher","unstructured":"Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.22918","DOI":"10.1002\/art.22918"},{"key":"202_CR29","doi-asserted-by":"publisher","unstructured":"Wendling D, Paccou J, Berthelot JM et al (2011) New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. https:\/\/doi.org\/10.1016\/j.semarthrit.2011.05.005","DOI":"10.1016\/j.semarthrit.2011.05.005"},{"issue":"8","key":"202_CR30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3109\/02713683.2010.486520","volume":"35","author":"V Kakkassery","year":"2010","unstructured":"Kakkassery V, Mergler S, Pleyer U (2010) Anti-TNF-\u03b1 treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 35(8):751\u2013756. https:\/\/doi.org\/10.3109\/02713683.2010.486520","journal-title":"Curr Eye Res"},{"issue":"2","key":"202_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3899\/jrheum.110865","volume":"39","author":"C Gaujoux-Viala","year":"2012","unstructured":"Gaujoux-Viala C, Giampietro C, Gaujoux T et al (2012) Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol 39(2):233\u2013239. https:\/\/doi.org\/10.3899\/jrheum.110865","journal-title":"J Rheumatol"},{"key":"202_CR32","doi-asserted-by":"publisher","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. https:\/\/doi.org\/10.1016\/j.berh.2008.09.008","DOI":"10.1016\/j.berh.2008.09.008"},{"issue":"2","key":"202_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamaophthalmol.2018.5413","volume":"137","author":"HMT Teo","year":"2019","unstructured":"Teo HMT, de S\u00e1 FF, Demirci H (2019) Association of blepharitis and ectropion with tumor necrosis factor \u03b1 inhibitor treatment in Crohn disease. JAMA Ophthalmol 137(2):232. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.5413","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"202_CR34","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","volume":"52","author":"R Seror","year":"2013","unstructured":"Seror R, Richez C, Sordet C et al (2013) Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a French national survey. Rheumatology 52(5):868\u2013874. https:\/\/doi.org\/10.1093\/rheumatology\/kes375","journal-title":"Rheumatology"},{"key":"202_CR35","doi-asserted-by":"publisher","unstructured":"Chakravorty M, Obaid S (2018) 16.\u2003A rare case of CNS demyelination with anti-TNF treatment. Rheumatol Adv Pract 2(suppl_1). https:\/\/doi.org\/10.1093\/rap\/rky033.008","DOI":"10.1093\/rap\/rky033.008"},{"issue":"1","key":"202_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3109\/09273972.2014.999796","volume":"23","author":"J Drury","year":"2015","unstructured":"Drury J, Hickman SJ (2015) Internuclear ophthalmoplegia associated with anti-TNF\u03b1 medication. Strabismus 23(1):30\u201332. https:\/\/doi.org\/10.3109\/09273972.2014.999796","journal-title":"Strabismus"},{"key":"202_CR37","doi-asserted-by":"crossref","unstructured":"Montero JA, Ruiz-Moreno JM, Rodr\u00edguez AE, Ferrer C, Sanchis E, Alio JL Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy. Eur J Ophthalmol 16(2):343\u2013345. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16703558","DOI":"10.1177\/112067210601600225"},{"key":"202_CR38","doi-asserted-by":"crossref","unstructured":"Agarwal PK, Gallaghar M, Murphy E, Virdi M Endogenous endophthalmitis in a rheumatoid patient on tumor necrosis factor alpha blocker. Indian J Ophthalmol 55, 230(3):\u2013232. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17456948","DOI":"10.4103\/0301-4738.31951"},{"key":"202_CR39","doi-asserted-by":"publisher","unstructured":"Da\u00efen CI, Monnier A, Claudepierre P et al (2009) Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/kep046","DOI":"10.1093\/rheumatology\/kep046"},{"key":"202_CR40","first-page":"645","volume":"21","author":"PJ Hashkes","year":"2003","unstructured":"Hashkes PJ, Shajrawi I (2003) Sarcoid-related uveitis occuring during etanercept therapy. Clin Exp Rheumatol 21:645","journal-title":"Clin Exp Rheumatol"},{"key":"202_CR41","doi-asserted-by":"publisher","unstructured":"Seve P, Varron L, Broussolle C, Denis P, Kodjikian L (2012) Sarcoid-related uveitis occurring during adalimumab therapy. Ocul Immunol Inflamm. https:\/\/doi.org\/10.3109\/09273948.2011.623213","DOI":"10.3109\/09273948.2011.623213"},{"key":"202_CR42","doi-asserted-by":"publisher","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Mu\u00f1oz S et al (2007) Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore). https:\/\/doi.org\/10.1097\/MD.0b013e3181441a68","DOI":"10.1097\/MD.0b013e3181441a68"},{"key":"202_CR43","doi-asserted-by":"publisher","unstructured":"Scrivo R, Spadaro A, Spinelli FR, Valesini G (2008) Uveitis following the use of tumor necrosis factor \u03b1 inhibitors: comment on the article by Lim et al. Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.23440","DOI":"10.1002\/art.23440"},{"key":"202_CR44","doi-asserted-by":"publisher","unstructured":"Sfikakis PP, Markomichelakis N (2008) Tumor necrosis factor inhibitors and uveitis: comment on the article by Lim et al. Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.23442","DOI":"10.1002\/art.23442"},{"issue":"12","key":"202_CR45","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/ard.2006.052092","volume":"65","author":"S Guignard","year":"2006","unstructured":"Guignard S, Gossec L, Salliot C et al (2006) Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 65(12):1631\u20131634. https:\/\/doi.org\/10.1136\/ard.2006.052092","journal-title":"Ann Rheum Dis"},{"key":"202_CR46","doi-asserted-by":"publisher","unstructured":"Cunningham ET, Pasadhika S, Suhler EB, Zierhut M (2012) Drug-induced inflammation in patients on TNF\u03b1 inhibitors. Ocul Immunol Inflamm. https:\/\/doi.org\/10.3109\/09273948.2011.644383","DOI":"10.3109\/09273948.2011.644383"},{"key":"202_CR47","doi-asserted-by":"publisher","unstructured":"Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega H (2008) Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard.2007.077370","DOI":"10.1136\/ard.2007.077370"},{"key":"202_CR48","doi-asserted-by":"publisher","unstructured":"Reddy AR, Backhouse OC. Does etanercept induce uveitis? [11]. Br J Ophthalmol. 2003. doi:https:\/\/doi.org\/10.1136\/bjo.87.7.925","DOI":"10.1136\/bjo.87.7.925"},{"key":"202_CR49","doi-asserted-by":"publisher","unstructured":"Taban M, Dupps W, Mandell B, Perez V (2006) Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm. https:\/\/doi.org\/10.1080\/09273940600659393","DOI":"10.1080\/09273940600659393"},{"key":"202_CR50","doi-asserted-by":"publisher","unstructured":"Palucka AK, Blanck J-P, Bennett L, Pascual V, Banchereau J (2005) Cross-regulation of TNF and IFN in autoimmune diseases. Proc Natl Acad Sci. https:\/\/doi.org\/10.1073\/pnas.0408506102","DOI":"10.1073\/pnas.0408506102"},{"issue":"3","key":"202_CR51","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","volume":"36","author":"DE Furst","year":"2006","unstructured":"Furst DE, Wallis R, Broder M, Beenhouwer DO (2006) Tumor necrosis factor antagonists: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36(3):159\u2013167. https:\/\/doi.org\/10.1016\/j.semarthrit.2006.02.001","journal-title":"Semin Arthritis Rheum"},{"key":"202_CR52","doi-asserted-by":"publisher","unstructured":"L\u00fcgering A, Schmidt M, L\u00fcgering N, Pauels HG, Domschke W, Kucharzik T (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn\u2019s disease by using a caspase-dependent pathway. Gastroenterology. https:\/\/doi.org\/10.1053\/gast.2001.28702","DOI":"10.1053\/gast.2001.28702"},{"issue":"5","key":"202_CR53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.semarthrit.2005.01.009","volume":"34","author":"RS Wallis","year":"2005","unstructured":"Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34(5):34\u201338. https:\/\/doi.org\/10.1016\/j.semarthrit.2005.01.009","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"202_CR54","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117(2):244\u2013279. https:\/\/doi.org\/10.1016\/j.pharmthera.2007.10.001","journal-title":"Pharmacol Ther"},{"key":"202_CR55","doi-asserted-by":"publisher","unstructured":"Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J (2003) Up regulation of the production of tumour necrosis factor \u03b1 and interferon \u03b3 by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard.62.6.561","DOI":"10.1136\/ard.62.6.561"},{"key":"202_CR56","doi-asserted-by":"publisher","unstructured":"Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J (2003) Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.10847","DOI":"10.1002\/art.10847"},{"key":"202_CR57","doi-asserted-by":"publisher","unstructured":"Sieper J, Van Den Brande J. Diverse effects of infliximab and etanercept on T lymphocytes. In: Seminars in arthritis and rheumatism.; 2005. doi:https:\/\/doi.org\/10.1016\/j.semarthrit.2005.01.006","DOI":"10.1016\/j.semarthrit.2005.01.006"},{"issue":"2","key":"202_CR58","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1124\/jpet.301.2.418","volume":"301","author":"B Scallon","year":"2002","unstructured":"Scallon B (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301(2):418\u2013426. https:\/\/doi.org\/10.1124\/jpet.301.2.418","journal-title":"J Pharmacol Exp Ther"},{"key":"202_CR59","doi-asserted-by":"publisher","unstructured":"Evans TJ (2004) Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram- negative sepsis. J Exp Med. https:\/\/doi.org\/10.1084\/jem.180.6.2173","DOI":"10.1084\/jem.180.6.2173"},{"issue":"4","key":"202_CR60","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/ncprheum0454","volume":"3","author":"JR Smith","year":"2007","unstructured":"Smith JR, Mackensen F, Rosenbaum JT (2007) Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol 3(4):219\u2013226. https:\/\/doi.org\/10.1038\/ncprheum0454","journal-title":"Nat Clin Pract Rheumatol"},{"key":"202_CR61","doi-asserted-by":"publisher","unstructured":"Hamideh F, Prete PE (2001) Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum. https:\/\/doi.org\/10.1053\/sarh.2001.16639","DOI":"10.1053\/sarh.2001.16639"},{"issue":"7","key":"202_CR62","doi-asserted-by":"publisher","first-page":"511.e1","DOI":"10.1016\/j.jfo.2009.04.029","volume":"32","author":"J Le Garrec","year":"2009","unstructured":"Le Garrec J, Marcelli C, Mouriaux F (2009) Les anti-Tnf peuvent-ils induire des scl\u00e9ro-uv\u00e9ites ? J Fr Ophtalmol 32(7):511.e1\u2013511.e6. https:\/\/doi.org\/10.1016\/j.jfo.2009.04.029","journal-title":"J Fr Ophtalmol"},{"key":"202_CR63","doi-asserted-by":"publisher","unstructured":"Yokoyama W, Takada K, Miyasaka N, Kohsaka H (2014) Myelitis and optic neuritis induced by a long course of etanercept in a patient with rheumatoid arthritis. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2014-205779","DOI":"10.1136\/bcr-2014-205779"},{"key":"202_CR64","doi-asserted-by":"publisher","unstructured":"Noguera-Pons R, Borr\u00e1s-Blasco J, Romero-Crespo I, Ant\u00f3n-Torres R, Navarro-Ruiz A, Gonz\u00e1lez-Ferrandez JA (2005) Optic neuritis with concurrent etanercept and isoniazid therapy. Ann Pharmacother. https:\/\/doi.org\/10.1345\/aph.1G279","DOI":"10.1345\/aph.1G279"},{"issue":"9","key":"202_CR65","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/ard.2006.066787","volume":"66","author":"I Simsek","year":"2007","unstructured":"Simsek I, Erdem H, Pay S, Sobaci G, Dinc A (2007) Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 66(9):1255\u20131258. https:\/\/doi.org\/10.1136\/ard.2006.066787","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"202_CR66","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jaapos.2005.12.002","volume":"10","author":"T Tauber","year":"2006","unstructured":"Tauber T, Turetz J, Barash J, Avni I, Morad Y (2006) Optic neuritis associated with etanercept therapy for juvenile arthritis. J Am Assoc Pediatr Ophthalmol Strabismus 10(1):26\u201329. https:\/\/doi.org\/10.1016\/j.jaapos.2005.12.002","journal-title":"J Am Assoc Pediatr Ophthalmol Strabismus"},{"key":"202_CR67","doi-asserted-by":"publisher","unstructured":"Couderc M, Mathieu S, Tournadre A, Dubost JJ, Soubrier M (2014) Acute ocular myositis occurring under etanercept for rheumatoid arthritis. Jt Bone Spine. https:\/\/doi.org\/10.1016\/j.jbspin.2014.03.003","DOI":"10.1016\/j.jbspin.2014.03.003"},{"key":"202_CR68","unstructured":"Caramaschi P, Biasi D, Carletto A, Bambara LM Orbital myositis in a rheumatoid arthritis patient during etanercept treatment. Clin Exp Rheumatol 21(1):136\u2013137 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12673906."},{"issue":"5","key":"202_CR69","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/ecco-jcc\/jjv030","volume":"9","author":"MB Singla","year":"2015","unstructured":"Singla MB, Hodge DK, Moawad FJ (2015) Infliximab-induced anterior uveitis in a patient with ulcerative colitis. J Crohn\u2019s Colitis 9(5):432\u2013432. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv030","journal-title":"J Crohn\u2019s Colitis"},{"issue":"5","key":"202_CR70","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/aos.12515","volume":"93","author":"A Grzybowski","year":"2015","unstructured":"Grzybowski A, Z\u00fclsdorff M, Wilhelm H, Tonagel F (2015) Toxic optic neuropathies: an updated review. Acta Ophthalmol 93(5):402\u2013410. https:\/\/doi.org\/10.1111\/aos.12515","journal-title":"Acta Ophthalmol"},{"key":"202_CR71","doi-asserted-by":"publisher","unstructured":"Thomas DA (2003) Retrobulbar optic neuritis associated with infliximab. J Neuro-Ophthalmology. https:\/\/doi.org\/10.1097\/00041327-200303000-00028","DOI":"10.1097\/00041327-200303000-00028"},{"issue":"5","key":"202_CR72","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjw003","volume":"10","author":"B Alexandre","year":"2016","unstructured":"Alexandre B, Vandermeeren Y, Dewit O et al (2016) Optic neuritis associated or not with TNF antagonists in patients with inflammatory bowel disease. J Crohn\u2019s Colitis 10(5):541\u2013548. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw003","journal-title":"J Crohn\u2019s Colitis"},{"issue":"7389","key":"202_CR73","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/bmj.326.7389.579","volume":"326","author":"MPM ten Tusscher","year":"2003","unstructured":"ten Tusscher MPM, Jacobs PJC, Busch MJWM, de Graaf L, Diemont WL (2003) Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 326(7389):579. https:\/\/doi.org\/10.1136\/bmj.326.7389.579","journal-title":"BMJ"},{"key":"202_CR74","doi-asserted-by":"publisher","unstructured":"Chan JW, Castellanos A (2010) Infliximab and anterior optic neuropathy: case report and review of the literature. Graefe\u2019s Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-009-1227-y","DOI":"10.1007\/s00417-009-1227-y"},{"key":"202_CR75","doi-asserted-by":"publisher","unstructured":"Simsek I, Erdem H, Pay S, Sobaci G, Dinc A (2007) Optic neuritis occurring with anti-tumour necrosis factor \u03b1 therapy. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard.2006.066787","DOI":"10.1136\/ard.2006.066787"},{"key":"202_CR76","doi-asserted-by":"publisher","unstructured":"Clemmensen K, Akrawi N, Stawowy M (2015) Irreversible optic neuritis after infliximab treatment in a patient with ulcerative colitis. Scand J Gastroenterol. https:\/\/doi.org\/10.3109\/00365521.2015.1063155","DOI":"10.3109\/00365521.2015.1063155"},{"key":"202_CR77","doi-asserted-by":"publisher","unstructured":"Ouakaa-Kchaou A, Gargouri D, Trojet S et al (2009) Retrobulbar optic neuritis associated with infliximab in a patient with Crohn\u2019s disease. J Crohn\u2019s Colitis. https:\/\/doi.org\/10.1016\/j.crohns.2009.02.007","DOI":"10.1016\/j.crohns.2009.02.007"},{"issue":"3","key":"202_CR78","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.lpm.2016.11.020","volume":"46","author":"A Landais","year":"2017","unstructured":"Landais A, Fanhan R (2017) Optic neuritis associated to treatment with infliximab. Presse Med 46(3):337\u2013341. https:\/\/doi.org\/10.1016\/j.lpm.2016.11.020","journal-title":"Presse Med"},{"issue":"2","key":"202_CR79","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0181-5512(05)81044-7","volume":"28","author":"THC Tran","year":"2005","unstructured":"Tran THC, Milea D, Cassoux N, Bodaghi B, Bourgeois P, LeHoang P (2005) Optic neuritis associated with infliximab. J Fr Ophtalmol 28(2):201\u2013204 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15851955.","journal-title":"J Fr Ophtalmol"},{"key":"202_CR80","doi-asserted-by":"publisher","unstructured":"Schiedler V, Scott IU, Flynn HW, Davis JL, Benz MS, Miller D (2004) Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am J Ophthalmol. https:\/\/doi.org\/10.1016\/j.ajo.2003.11.013","DOI":"10.1016\/j.ajo.2003.11.013"},{"issue":"2","key":"202_CR81","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10792-017-0532-4","volume":"38","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Yokokura S, Kunikata H et al (2018) Endophthalmitis associated with Purpureocillium lilacinum during infliximab treatment for surgically induced necrotizing scleritis, successfully treated with 27-gauge vitrectomy. Int Ophthalmol 38(2):841\u2013847. https:\/\/doi.org\/10.1007\/s10792-017-0532-4","journal-title":"Int Ophthalmol"},{"issue":"5","key":"202_CR82","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12664-011-0130-8","volume":"30","author":"R Kochhar","year":"2011","unstructured":"Kochhar R, Gupta V, Dutta U, Singh K, Kochhar R (2011) Infliximab induced endophthalmitis in a patient of fistulizing Crohn\u2019s disease. Indian J Gastroenterol 30(5):241\u2013242. https:\/\/doi.org\/10.1007\/s12664-011-0130-8","journal-title":"Indian J Gastroenterol"},{"issue":"1","key":"202_CR83","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1869-5760-3-50","volume":"3","author":"X Jin","year":"2013","unstructured":"Jin X, Namba K, Saito W, Iwata D, Ishida S (2013) Bacterial endophthalmitis caused by an intraocular cilium in a patient under treatment with infliximab. J Ophthalmic Inflamm Infect 3(1):50. https:\/\/doi.org\/10.1186\/1869-5760-3-50","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"202_CR84","unstructured":"Top 50 pharmaceutical products by global sales - Top Pharma List - PMLiVE. 2014. http:\/\/www.pmlive.com\/top_pharma_list\/Top_50_pharmaceutical_products. ."},{"key":"202_CR85","unstructured":"Fda, Cder. Center for drug evaluation and research approval Package For. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/bla\/2014\/125057Orig1s381.pdf. Accessed 29 May 2019."},{"key":"202_CR86","doi-asserted-by":"publisher","unstructured":"Tsilimbaris M, Diakonis VF, Naoumidi I et al (2009) Evaluation of potential retinal toxicity of adalimumab (Humira). Graefe\u2019s Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-009-1065-y","DOI":"10.1007\/s00417-009-1065-y"},{"key":"202_CR87","doi-asserted-by":"publisher","unstructured":"Manzano RPA, Peyman GA, Carvounis PE et al (2008) Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefe\u2019s Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-008-0765-z","DOI":"10.1007\/s00417-008-0765-z"},{"key":"202_CR88","doi-asserted-by":"publisher","unstructured":"Manzano RPA, Peyman GA, Carvounis PE et al (2011) Toxicity of high-dose intravitreal adalimumab (Humira) in the rabbit. J Ocul Pharmacol Ther. https:\/\/doi.org\/10.1089\/jop.2010.0174","DOI":"10.1089\/jop.2010.0174"},{"key":"202_CR89","doi-asserted-by":"publisher","unstructured":"Myers AC, Ghosh F, Andre\u00e1sson S, Ponjavic V (2014) Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab. Curr Eye Res. https:\/\/doi.org\/10.3109\/02713683.2014.898309","DOI":"10.3109\/02713683.2014.898309"},{"key":"202_CR90","doi-asserted-by":"publisher","unstructured":"de Paula \u00c1C, de \u00c1vila MP, DLC I et al (2015) Cytotoxicity and genotoxicity of intravitreal adalimumab administration in rabbit retinal cells. Arq Bras Oftalmol. https:\/\/doi.org\/10.5935\/0004-2749.20150024","DOI":"10.5935\/0004-2749.20150024"},{"key":"202_CR91","doi-asserted-by":"publisher","unstructured":"Matet A, Daruich A, Beydoun T, Cosnes J, Bourges J-L (2015) Systemic adalimumab induces peripheral corneal infiltrates: a case report. BMC Ophthalmol 15. https:\/\/doi.org\/10.1186\/S12886-015-0047-6","DOI":"10.1186\/S12886-015-0047-6"},{"key":"202_CR92","doi-asserted-by":"publisher","unstructured":"Saffra N, Astafurov K (2017) Visual loss induced by adalimumab used for plaque psoriasis. Case Rep Dermatol. https:\/\/doi.org\/10.1159\/000461572","DOI":"10.1159\/000461572"},{"key":"202_CR93","doi-asserted-by":"publisher","unstructured":"Li SY, Birnbaum AD, Goldstein DA (2010) Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm. https:\/\/doi.org\/10.3109\/09273948.2010.495814","DOI":"10.3109\/09273948.2010.495814"},{"issue":"1-2","key":"202_CR94","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jns.2006.01.012","volume":"244","author":"JH Chung","year":"2006","unstructured":"Chung JH, Van Stavern GP, Frohman LP, Turbin RE (2006) Adalimumab-associated optic neuritis. J Neurol Sci 244(1-2):133\u2013136. https:\/\/doi.org\/10.1016\/j.jns.2006.01.012","journal-title":"J Neurol Sci"},{"key":"202_CR95","doi-asserted-by":"publisher","unstructured":"Von Jagow B, Kohnen T (2008) Anterior optic neuropathy associated with adalimumab. Ophthalmologica. https:\/\/doi.org\/10.1159\/000140257","DOI":"10.1159\/000140257"},{"key":"202_CR96","doi-asserted-by":"publisher","unstructured":"Kim A, Saffra N (2012) A case report of adalimumab-associated optic neuritis. J Ophthalmic Inflamm Infect. https:\/\/doi.org\/10.1007\/s12348-011-0058-2","DOI":"10.1007\/s12348-011-0058-2"},{"issue":"4","key":"202_CR97","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/ICB.0000000000000499","volume":"12","author":"SA Schechet","year":"2018","unstructured":"Schechet SA, Garff K, Klima K, Campbell W, Schocket LS (2018) Acute retinal necrosis after administration of adalimumab, a systemic antitumor necrosis factor antibody. Retin Cases Brief Rep 12(4):307\u2013309. https:\/\/doi.org\/10.1097\/ICB.0000000000000499","journal-title":"Retin Cases Brief Rep"},{"issue":"9","key":"202_CR98","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.crohns.2012.03.015","volume":"6","author":"P Marticorena-\u00c1lvarez","year":"2012","unstructured":"Marticorena-\u00c1lvarez P, Chaparro M, P\u00e9rez-Casas A, Muriel-Herrero A, Gisbert JP (2012) Probable diffuse retinopathy caused by adalimumab in a patient with Crohn\u2019s disease. J Crohn\u2019s Colitis 6(9):950\u2013953. https:\/\/doi.org\/10.1016\/j.crohns.2012.03.015","journal-title":"J Crohn\u2019s Colitis"},{"key":"202_CR99","doi-asserted-by":"publisher","unstructured":"Achermann Y, Goldstein EJC, Coenye T, Shirtliffa ME (2014) Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen. Clin Microbiol Rev. https:\/\/doi.org\/10.1128\/CMR.00092-13","DOI":"10.1128\/CMR.00092-13"},{"key":"202_CR100","doi-asserted-by":"publisher","unstructured":"Drury J, Hickman SJ (2015) Internuclear ophthalmoplegia associated with anti-TNF\u03b1 medication. Strabismus. https:\/\/doi.org\/10.3109\/09273972.2014.999796","DOI":"10.3109\/09273972.2014.999796"},{"issue":"1","key":"202_CR101","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ajo.2012.06.023","volume":"155","author":"KL Winthrop","year":"2013","unstructured":"Winthrop KL, Chen L, Fraunfelder FW et al (2013) Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. Am J Ophthalmol 155(1):183\u2013189.e1. https:\/\/doi.org\/10.1016\/j.ajo.2012.06.023","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"202_CR102","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.gastrohep.2018.04.005","volume":"41","author":"JP Gisbert","year":"2018","unstructured":"Gisbert JP, Chaparro M (2018 Jun - Jul) Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: can it be recommended? A systematic review. Gastroenterol Hepatol 41(6):389\u2013405. https:\/\/doi.org\/10.1016\/j.gastrohep.2018.04.005","journal-title":"Gastroenterol Hepatol"},{"key":"202_CR103","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.3389\/fphar.2019.01468","volume":"10","author":"C Fabiani","year":"2019","unstructured":"Fabiani C, Vitale A, Emmi G et al (2019) The role of biosimilars in uveitis: long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors. Front Pharmacol 10:1468. https:\/\/doi.org\/10.3389\/fphar.2019.01468","journal-title":"Front Pharmacol"},{"key":"202_CR104","doi-asserted-by":"publisher","unstructured":"Thomas AS (2019) Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. https:\/\/doi.org\/10.1097\/ICU.0000000000000562","DOI":"10.1097\/ICU.0000000000000562"},{"key":"202_CR105","first-page":"3884","volume":"35","author":"S Nakamura","year":"1994","unstructured":"Nakamura S, Yamakawa T, Sugita M et al (1994) The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Investi Ophthalmol Vis Sci 35:3884","journal-title":"Investi Ophthalmol Vis Sci"},{"issue":"10","key":"202_CR106","first-page":"2911","volume":"34","author":"L Kasner","year":"1993","unstructured":"Kasner L, Chan CC, Whitcup SM, Gery I (1993) The paradoxical effect of tumor necrosis factor alpha (TNF-alpha) in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 34(10):2911\u20132917 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8360023.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"202_CR107","first-page":"658","volume":"39","author":"JR Smith","year":"1998","unstructured":"Smith JR, Hart PH, Coster DJ, Williams KA (1998) Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin induced uveitis. Investig Ophthalmol Vis Sci 39:658","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"202_CR108","doi-asserted-by":"publisher","unstructured":"Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J (1998) Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun. https:\/\/doi.org\/10.1006\/jaut.1998.0197","DOI":"10.1006\/jaut.1998.0197"},{"issue":"9","key":"202_CR109","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00417-007-0549-x","volume":"245","author":"A Fonollosa","year":"2007","unstructured":"Fonollosa A, Segura A, Giralt J, Garcia-Arumi J (2007) Tuberculous uveitis after treatment with etanercept. Graefe\u2019s Arch Clin Exp Ophthalmol 245(9):1397\u20131399. https:\/\/doi.org\/10.1007\/s00417-007-0549-x","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"202_CR110","unstructured":"The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS\/MRI Analysis Group, TNF neutralization in MS. Neurology. 1999;53457- 465"},{"key":"202_CR111","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2018-000250","volume":"4","author":"C Iwahashi","year":"2019","unstructured":"Iwahashi C, Ono H, Haruta M et al (2019) New onset or exacerbation of uveitis with infliximab: paradoxical effects? BMJ Open Ophthalmology 4:e000250. https:\/\/doi.org\/10.1136\/bmjophth-2018-000250","journal-title":"BMJ Open Ophthalmology"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-020-00202-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-020-00202-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-020-00202-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T23:10:23Z","timestamp":1619478623000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-020-00202-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["202"],"URL":"https:\/\/doi.org\/10.1186\/s12348-020-00202-6","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]},"assertion":[{"value":"7 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CP has received payments for lectures by AbbVie and works as a Consultant for Alimera Sciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}